ClinicalTrials.gg
TerminatedNCT05744193Updated Jul 9, 2024

Feeding Study in VLBW Premature Infants

An interventional study of Exempt Infant Formula in VLBW - Very Low Birth Weight Infant, sponsored by Mead Johnson Nutrition. Terminated at 6 sites in United States. Open to participants aged 168 Days to 224 Days. Per ClinicalTrials.gov, last updated 2024-07-09.

Sponsored by Mead Johnson Nutrition (part of Reckitt) · Not applicable, Interventional, and Supportive care

How we know

Why this study was terminated
Slow recruitment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
22
Allocation
Randomized
Ages
168 Days to 224 Days
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 32 studies in Birth Weight with a site in United States — 6 open to participants now, 6 under way, none of them phase 3. Birth Weight · United States.

Enrollment
14th of 19
22 · median 49
Started
2023
with 1 other
No phase
15 of 32
4 open now
Registered
26th of 32
by date

Among the 32 studies in Birth Weight with a site in United States, this one is the 14th largest by enrollment of the 19 interventional ones that give a count, is one of 2 that started in 2023, is one of 15 with no phase, and was the 26th registered.

Birth Weight

185 studies on the registry are indexed under Birth Weight; 24 are open to participants now.

Browse Birth Weight studies →

Open to participants now

6 of the 32 studies in Birth Weight with a site in United States are open now. Recruiting first, the newest first:

1 more — sign in →

All 6 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 18 Birth Weight studies recruiting now, 7 (39%) set no upper age limit and 11 (61%) stop at 75 or younger; 11 take children under 18; 4 take healthy volunteers.

This study: 168 Days to 224 Days · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 32 studies in Birth Weight with a site in United States, or all of them as a file.
02

Study summary

A multi-center, single-blind, randomized, controlled, parallel-designed, prospective trial to compare growth between preterm infants fed one of three study human milk fortifiers added to human milk

03

Conditions studied

  • VLBW - Very Low Birth Weight Infant

Browse trials for

04

Who can participate

Ages eligible
168 Days to 224 Days
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Clinically and metabolically stable
  • Birth weight 700 g to less than or equal to 1,250 g
  • Appropriate birth weight for gestational age
  • 24 0/7 to 32 0/7 weeks' gestational age at birth
  • Exclusively fed human milk
  • Signed and authorization to use and/or disclose PHI

Exclusion criteria

Exclusion Criteria:

  • Metabolic or chronic disease
  • 5-minute Apgar score \<4
  • Major surgery
  • Ventilator dependent
  • Fluid restriction
  • Grade III or IV intraventricular hemorrhage (IVH)
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Phase
Not applicable
Primary purpose
Supportive care
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Outcomes assessor)
Enrollment
22 participants (actual)

Study arms

  • Active comparator
    Commercial Liquid Human Milk Fortifier

    Liquid human milk fortifier to be added to human milk

    Other: Exempt Infant Formula

  • Experimental
    Liquid Human Milk Fortifier - Standard Protein

    Liquid human milk fortifier to be added to human milk

    Other: Exempt Infant Formula

  • Experimental
    Liquid Human Milk Fortifier - High Protein

    Liquid human milk fortifier to be added to human milk

    Other: Exempt Infant Formula

Interventions

  • OtherExempt Infant Formula

    Liquid human milk fortifier to be added to human milk daily

06

What researchers measure

Primary outcomes

  1. Weight gain

    grams/kg/day

    Time frame: Daily for 28 days

Secondary outcomes

  1. Feeding Tolerance

    Achievement of full enteral feeding, incidence of (TPN, Bloody stools, Feeding interruptions, Drop in feeding volume)

    Time frame: Daily for 28 days

  2. Rate of Length and head circumference gain

    cm/week

    Time frame: weekly up to day 28

  3. Total energy intake

    kcal

    Time frame: 28 days

  4. Total protein intake

    grams

    Time frame: 28 days

  5. Respiratory status

    Incidence of Apnea, Bradycardia, Supplemental oxygen/Continuous positive airway pressure/Nasal cannulation, Mechanical ventilation

    Time frame: 28 days

  6. Incidence of NEC

    Modified Bell's Staging Criteria

    Time frame: Study Day 0 through 28

  7. Incidence of sepsis - clinical symptoms

    Clinical symptoms - Changes in respiration, blood pressure, body temperature, stool, blood sugar and heart rate

    Time frame: Study Day 0 through 28

  8. Incidence of sepsis - culture for pathogens

    Culture for pathogens - no culture, culture-negative, culture-positive, presumed contaminant

    Time frame: Study day 0 through 28

  9. Incidence of sepsis - Antibiotic use

    Antibiotic use duration - less than 5 days ; 5 days or more

    Time frame: Study Day 0 through 28

  10. Total serum CO2

    less than 18 mmol/L

    Time frame: Study days 0, 14, 28

  11. Metabolic Acidosis

    If CO2 \<18 mmol/L then Blood gas; Acidity (pH), Carbon dioxide, partial pressure (pCO2; torr), Bicarbonate (mmol/L); Base Excess (mmol/L)

    Time frame: Study days 0, 14, 28

07

Study locations

6 sites
  • The University of Alabama at Birmingham
    Birmingham, Alabama 35233, United States
  • Augusta University
    Augusta, Georgia 30912, United States
  • Riley Children's Hospital
    Indianapolis, Indiana 46202, United States
  • NYU Langone Hospital, Long Island
    Mineola, New York 11501, United States
  • Cohen Children's Medical Center of NY
    New Hyde Park, New York 11040, United States
  • Weill Cornell Medicine
    New York, New York 10021, United States
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Jul 2023 to primary completion in May 2024, 10 months.

How these figures are worked out, and which studies are left out of them.

Registered
Jan 31, 2023
First posted
Feb 24, 2023
StartActual
Jul 10, 2023
Primary completionActual
May 31, 2024
CompletionActual
May 31, 2024
Last update
Jul 9, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 9, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT05744193
Responsible party
Sponsor
First posted
Feb 24, 2023
Start date
Jul 10, 2023
Primary completion
May 31, 2024
Completion
May 31, 2024
Last update
Jul 9, 2024

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is terminated, as verified in Jul 2024. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion